Functional Assay Panels

ChemPartner delivers integrated small molecule CMC services that support drug candidates from early development through IND, NDA, and commercialization. Our coordinated platform combines API development and manufacturing, formulation development, analytical characterization, solid-state R&D, process optimization, pilot-scale production, large-scale manufacturing, and quality management within a unified development strategy.

Pre-configured functional assay panels for rapid compound profiling. Run a candidate set across a defined panel and get comparable potency, selectivity and phenotype data in one dataset, rather than assembling results from assays run months and methods apart.

OVERVIEW

Everything a sponsor evaluating an outsourced biologics CMC partner needs to know — from capacity to compliance.

IDAssay TypeCell Type
1Mixed Lymphocyte Reaction (MLR)Primary human/mouse DC + T cells
2CMV antigen recallPrimary human T cells
3T cell activation (anti-CD3/CD28)Primary human/mouse T cells
4T cell activation (SEB super-antigen)Primary human T cells
5T cell and tumor cell co-culturePrimary human T cells + engineered tumor cells
6OT-I T cell and OVA tumor cell co-cultureT cells from OT-I mice + OVA-expressing tumor cells 
7Treg suppressive assayPrimary mouse T cells
8Treg differentiationPrimary human/mouse T cells
9Th1 differentiationPrimary human/mouse T cells
10Th2 differentiationPrimary human/mouse T cells
11Th17 differentiationPrimary human/mouse T cells
12M1/M2 Macrophage differentiationPrimary human/mouse macrophages
13Macrophage phagocytosisPrimary human/mouse macrophages
14Mouse T cell and M2 Macrophage co-culture Mouse T cells + M2 Macrophages
15NLRP3 activation assayMouse BMDM, human THP-1 cells
16Basophil activation assayHuman whole blood
17B cell activation and proliferationPrimary human/mouse B cells or whole blood
18Target specific reporter gene assay (41BB, etc.)Engineered cell lines
19Antibody-Dependent Cellular Cytotoxicity (ADCC)Primary human NK or NK-92-CD16 + target cells
20NK cell cytotoxicityPrimary human NK or NK-92-CD16 + target cells
21Complement Dependent Cytotoxicity (CDC)Complement + target cells
22ELISpotPrimary human PBMCs or mouse T cells or splenocytes or TILs Treated with anti-CD3 or peptides or peptide loaded APC or target cells
START YOUR JOURNEY
Phase
Modality
Therapeutic Area